Annexin A5 polymorphism (-1C->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome
- 1 November 2006
- journal article
- other
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 65 (11), 1468-1472
- https://doi.org/10.1136/ard.2005.045237
Abstract
Background: Annexin A5 is thought to have a role in the pathophysiology of the antiphospholipid syndrome (APS)—a syndrome characterised by recurrent thrombosis and pregnancy morbidity. Objective: To investigate whether anti-annexin A5 immunoglobulin (Ig)M or IgG antibodies, or the −1C→T polymorphism of annexin A5, is a risk factor for thrombosis or miscarriage, and whether the −1C→T polymorphism is correlated with APS. Methods: A cohort study was carried out with a population of 198 patients with primary APS, systemic lupus erythematosus or lupus-like disease. For the detection of anti-annexin A5 antibodies and the measurement of annexin A5 plasma levels, ELISA-type methods were used. The annexin A5 −1C→T mutation was detected by restriction fragment length polymorphism. Results: 71 patients were positive for annexin A5 IgM or IgG antibodies, of whom 53 patients were positive for anti-annexin A5 IgG antibodies and 27 of 198 patients were positive for anti-annexin A5 IgM antibodies. The prevalence of IgM or IgG anti-annexin A5 antibodies was not significantly associated with thrombosis or miscarriage on multivariate analysis. The prevalence of the −1C→T mutation in the annexin A5 gene (46/198 patients) was significantly associated with miscarriage (odds ratio 2.7, 95% confidence interval 1.1 to 6.7, independent risk factor). Conclusion: The detection of anti-annexin A5 antibodies does not seem relevant for estimating the risk for thrombosis or miscarriage in APS. The −1C→T mutation was an independent risk factor for miscarriage, which is independent of APS.This publication has 26 references indexed in Scilit:
- β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndromeBlood, 2004
- Faible prévalence des anticorps anti-annexine V dans le syndrome des antiphospholipides avec pertes fœtalesLa Revue de Médecine Interne, 1999
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndromeAmerican Journal of Obstetrics and Gynecology, 1999
- Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villiAmerican Journal of Obstetrics and Gynecology, 1997
- Pregnancy Loss in the Antiphospholipid-Antibody Syndrome — A Possible Thrombogenic MechanismThe New England Journal of Medicine, 1997
- Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.1996
- The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulationPlacenta, 1994
- Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome.1994
- Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).Proceedings of the National Academy of Sciences of the United States of America, 1990